Surame, first name        Dr. (Mrs.) HAAS JIMOH AKANBI, Marijke            
E-mail                 This email address is being protected from spambots. You need JavaScript enabled to view it.

Senior Lecturer at Department of Pharmacology and Therapeutics, Faculty of Basic Medical Science, College of Health Sciences, University of Ilorin, Nigeria, since 2008.

Head of Pharmacology/Preclinical Research Unit, BiOMade (Bio-Organic Materials and Devices) Technology Foundation, Groningen, the Netherlands, 2001 – 2008.

Post-doctoral associate, Department of Clinical Pharmacology, Nephrology and Pharmacokinetics (University Medical Center Groningen) and Drug Delivery of the University Center of Pharmacy (University of Groningen), Groningen, 1998 – 2001.

Ph.D. titled ‘Drug targeting to the kidney and urinary bladder’
Departments of Clinical Pharmacology and Nephrology (University Medical Center Groningen) and Pharmacokinetics and Drug Delivery of the University Center of Pharmacy (University of Groningen), Groningen, 1994 – 1997.


PUBLICATIONS (8 selected)

  1. L de Vries, CE Reitzema-Klein, A Meter-Arkema, A van Dam, R Rink, GN Moll, M Haas Jimoh Akanbi (2010). Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7). Peptides 31:893-898.
  2. M Haas Jimoh Akanbi, E Post, A Meter-Arkema, R Rink, GT Robillard, X Wang, HA Wösten, K Scholtmeijer (2010). Use of hydrophobins in formulation of water insoluble drugs for oral administration. Colloids and Surfaces.B, Biointerfaces 75:526-31.
  3. R Rink, A Arkema-Meter, I Baudoin, E Post, A Kuipers, SA Nelemans, M Haas Jimoh Akanbi, GN Moll (2010). To protect peptide pharmaceuticals against peptidases. Journal of Pharmacological and Toxicological Methods 61:210-218.
  4. LD Kluskens, SA Nelemans, R Rink, L de Vries, A Meter-Arkema, Y Wang, T Walther, A Kuipers, GN Moll, M Haas (2009). Angiotensin-(1-7) with thioether-bridge: an ACE-resistant, potent Ang-(1-7) analogue. J Pharmacol Exp Ther 328:1-6.
  5. J Prakash, AM van Loenen-Weemaes, M Haas, JH Proost, DKF Meijer, K Poelstra, RJ Kok (2005). Renal-selective delivery and ACE inhibition by subcutaneously administered captopril-lysozyme. Drug Metabolism and Disposition (Drug Metab Dispos) 33:683-688.
  6. M Haas, E de Boer, PE de Jong, F Moolenaar, DKF Meijer, D de Zeeuw (2003). Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat. Clinical Science 105: 51-57.
  7. M Haas, F Moolenaar, DKF Meijer, D de Zeeuw (2002). Specific drug delivery to the kidney. Cardiovascular Drugs and Therapy 16: 489-496 (review).
  8. M Haas, F Moolenaar, A Elsinga, E van der Wouden, PE de Jong, DKF Meijer, D de Zeeuw (2002). Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine with an absence of renal toxicity. Journal of Drug Targeting 10: 81-89.
  9. M Durik, R van Veghel, A Kuipers, R Rink, M Haas Jimoh Akanbi, GN Moll, AHJ Danser, AJ Roks   (2012):  The effect of the thio-ether bridged, stabilized angiotensin-(1-7) analogue cyclic Ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction.  International Journal of Hypertension 2012:1-8.